Cargando…
Blocking Bacterial Naphthohydroquinone Oxidation and ADP-Ribosylation Improves Activity of Rifamycins against Mycobacterium abscessus
Rifampicin is an effective drug for treating tuberculosis (TB) but is not used to treat Mycobacterium abscessus infections due to poor in vitro activity. While rifabutin, another rifamycin, has better anti-M. abscessus activity, its activity is far from the nanomolar potencies of rifamycins against...
Autores principales: | Ganapathy, Uday S., Lan, Tian, Krastel, Philipp, Lindman, Marissa, Zimmerman, Matthew D., Ho, HsinPin, Sarathy, Jansy P., Evans, Joanna C., Dartois, Véronique, Aldrich, Courtney C., Dick, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370238/ https://www.ncbi.nlm.nih.gov/pubmed/34228543 http://dx.doi.org/10.1128/AAC.00978-21 |
Ejemplares similares
-
Blocking ADP-ribosylation expands the anti-mycobacterial spectrum of rifamycins
por: Ganapathy, Uday S., et al.
Publicado: (2023) -
Kanglemycin A Can Overcome Rifamycin Resistance Caused by ADP-Ribosylation by Arr Protein
por: Harbottle, John, et al.
Publicado: (2021) -
ADP-ribosylation-resistant rifabutin analogs show improved bactericidal activity against drug-tolerant M. abscessus in caseum surrogate
por: Xie, Min, et al.
Publicado: (2023) -
Redesign of Rifamycin Antibiotics to Overcome ADP‐Ribosylation‐Mediated Resistance
por: Lan, Tian, et al.
Publicado: (2022) -
Molecular Analysis of Linezolid-Resistant Clinical Isolates of Mycobacterium abscessus
por: Ye, Meiping, et al.
Publicado: (2019)